Serotonin2c receptors and the motor control of oral activity

Current Neuropharmacology

Volumn 11, Issue 2, 2013, Pages 160-170

  Lagière, Mélanie ^a,b   Navailles, Sylvia ^a,b   Bosc, Marion ^a,b   Guthrie, Martin ^a,b   de Deurwaerdère, Philippe ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

6 hydroxydopamine lesion; Hypersensitized oral responses; Neuroleptic; Oral activity; Serotonin2c receptor

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL) PIPERAZINE; 1, 2, 3, 4, 8, 9, 10, 10A OCTAHYDRO 7BH CYCLOPENTA [B] [1, 4] DIAZEPINO [6, 7, 1 HI] INDOLE; 1, 2, 3, 5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL) PYRROLO [2, 3 F] INDOLE; 1,2,3,4,8,9,10,10A OCTAHYDRO 7BH CYCLOPENTA[B][1,4]DIAZEPINO[6,7,1 HI]INDOLE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 4, 5, 7A, 8, 9, 10, 11, 11A OCTAHYDRO 10 METHYL 7H INDOLO [1, 7 BC] [2, 6] NAPHTHYRIDINE; 4,5,7A,8,9,10,11,11A OCTAHYDRO 10 METHYL 7H INDOLO[1,7 BC][2,6]NAPHTHYRIDINE; 5 HYDROXYDOPAMINE; 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; HALOPERIDOL; MESULERGINE; MIANSERIN; NEUROLEPTIC AGENT; QUIPAZINE; RITANSERIN; RO 60; S 32006; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BASAL GANGLION; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DYSKINESIA; HUMAN; LOCOMOTION; MOTOR CONTROL; MOVEMENT (PHYSIOLOGY); NONHUMAN; OROFACIAL MOVEMENT; PARKINSON DISEASE; SUBTHALAMIC NUCLEUS;

EID: 84876739761     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X11311020003     Document Type: Article

References (118)

1. Hoyer, D.; Hannon, J.P.; Martin, G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav., 2002, 71(4), 533-554.
2. Pazos, A.; Cortes, R.; Palacios, J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res., 1985, 346(2), 231-249.
3. Tecott, L.H.; Sun, L.M.; Akana, S.F.; Strack, A.M.; Lowenstein, D.H.; Dallman, M.F.; Julius, D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature, 1995, 374(6522), 542-546.
4. De Deurwaerdere, P.; Le Moine, C.; Chesselet, M.F. Selective blockade of serotonin 2C receptor enhances Fos expression specifically in the striatum and the subthalamic nucleus within the basal ganglia. Neurosci. Lett., 2010, 469(2), 251-255.
5. Lefkowitz, R.J.; Cotecchia, S.; Samama, P.; Costa, T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci., 1993, 14(8), 303-307.
6. Giorgetti, M.; Tecott, L.H. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur. J. Pharmacol., 2004, 488(1-3), 1-9.
7. Huot, P.; Fox, S.H.; Brotchie, J.M. The serotonergic system in Parkinson's disease. Prog. Neurobiol., 2011, 95(2), 163-212.
8. Kostrzewa, R.M.; Huang, N.Y.; Kostrzewa, J.P.; Nowak, P.; Brus, R. Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment. Neurotox. Res., 2007, 11(1), 41-50.
9. Meltzer, H.Y.; Sun, L.; Hashimoto, H. The 5-HT2C Receptor as a target for Schizophrenia. In: 5-HT2C Receptors in the pathophysiology of Central Nervous of System disease, Di Giovanni, G., Di Matteo, V., Esposito, E., Eds.; Springer; 2010, pp. 275-292.
10. Bersani, G.; Grispini, A.; Marini, S.; Pasini, A.; Valducci, M.; Ciani, N. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin. Neuropharmacol., 1990, 13(6), 500-506.
11. Ikeguchi, K.; Kuroda, A. Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur. Arch. Psychiatry Clin. Neurosci., 1995, 244(6), 320-324.
12. Meco, G.; Fabrizio, E.; Di Rezze, S.; Alessandri, A.; Pratesi, L. Mirtazapine in L-dopa-induced dyskinesias. Clin. Neuropharmacol., 2003, 26(4), 179-181.
13. Bubar, M.J.; Cunningham, K.A. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse. Prog. Brain Res., 2008, 172, 319-346.
14. Grottick, A.J.; Fletcher, P.J.; Higgins, G.A. Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior. J. Pharmacol. Exp. Ther., 2000, 295(3), 1183-1191.
15. Mink, J.W. The basal ganglia: focused selection and inhibition of competing motor programs. Prog. Neurobiol., 1996, 50(4), 381-425.
16. Murphy, D.L.; Lesch, K.P.; Aulakh, C.S.; Pigott, T.A. Serotoninselective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol. Rev., 1991, 43(4), 527-552.
17. Rupniak, M.N.; Jenner, P.; Marsden, C.D. The effect of chronic neuroleptic administration on cerebral dopamine receptor function. Life Sci, 1983, 32(20), 2289-2311.
18. Cenci, M.A.; Konradi, C. Maladaptive striatal plasticity in LDOPA- induced dyskinesia. Prog. Brain Res., 2010, 183, 209-233.
19. Salamone, J.D.; Mayorga, A.J.; Trevitt, J.T.; Cousins, M.S.; Conlan, A.; Nawab, A. Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog. Neurobiol, 1998, 56(6), 591-611.
20. Stewart, B.R.; Jenner, P.; Marsden, C.D. Induction of purposeless chewing behavior in rats by 5-HT agonist drugs. Eur. J. Pharmacol., 1989, 162(1), 101-107.
21. Cath, D.C.; Gijsman, H.J.; Schoemaker, R.C.; van Griensven, J.M.; Troost, N.; van Kempen, G.M.; Cohen, A.F. The effect of m-CPP on tics and obsessive-compulsive phenomena in Gilles de la Tourette syndrome. Psychopharmacology (Berl), 1999, 144(2), 137-143.
22. Martin, J.R.; Bos, M.; Jenck, F.; Moreau, J.; Mutel, V.; Sleight, A.J.; Wichmann, J.; Andrews, J.S.; Berendsen, H.H.; Broekkamp, C.L.; Ruigt, G.S.; Kohler, C.; Delft, A.M. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J. Pharmacol. Exp.Ther., 1998, 286(2), 913-924.
23. Prinssen, E.P.; Balestra, W.; Bemelmans, F.F.; Cools, A.R. Evidence for a role of the shell of the nucleus accumbens in oral behavior of freely moving rats. J. Neurosci., 1994, 14(3 Pt 2), 1555-1562.
24. Rupniak, N.M.; Briggs, R.S.; Petersen, M.M.; Mann, S.; Reavill, C.; Jenner, P.; Marsden, C.D. Differential alterations in striatal acetylcholine function in rats during 12 months' continuous administration of haloperidol, sulpiride, or clozapine. Clin. Neuropharmacol., 1986, 9(3), 282-292.
25. Graf, M. 5-HT2c receptor activation induces grooming behavior in rats: possible correlations with obsessive-compulsive disorder. Neuropsychopharmacol. Hung, 2006, 8(1), 23-28.
26. Gunes, A.; Dahl, M.L.; Spina, E.; Scordo, M.G. Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur. J. Clin. Pharmacol., 2008, 64(5), 477-482.
27. Zhang, Z.J.; Zhang, X.B.; Sha, W.W.; Reynolds, G.P. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol. Psychiatry, 2002, 7(7), 670-671.
28. Dehning, S.; Muller, N.; Matz, J.; Bender, A.; Kerle, I.; Benninghoff, J.; Musil, R.; Spellmann, I.; Bondy, B.; Moller, H.J.; Riedel, M.; Zill, P. A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome. Psychiatr. Genet., 2010, 20(1), 35-38.
29. Gong, L.; Kostrzewa, R.M. Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats. Pharmacol. Biochem. Behav., 1992, 41(3), 621-623.
30. Gong, L.; Kostrzewa, R.M.; Fuller, R.W.; Perry, K.W. Supersensitization of the oral response to SKF 38393 in neonatal 6- OHDA-lesioned rats is mediated through a serotonin system. J. Pharmacol. Exp. Ther., 1992, 261(3), 1000-1007.
31. Navailles, S.; Lagiere, M.; Roumegous, A.; Polito, M.; Boujema, M.B.; Cador, M.; Dunlop, J.; Chesselet, M.F.; Millan, M.J.; De Deurwaerdere, P. Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinson's disease. Int. J. Neuropsychopharmacol., 2012, 1-14.
32. Kahn, R.S.; Wetzler, S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol. Psychiatry, 1991, 30(11), 1139-1166.
33. Eberle-Wang, K.; Lucki, I.; Chesselet, M.F. A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia. Neuroscience, 1996, 72(1), 117-128.
34. Wolf, W.A.; Bieganski, G.J.; Guillen, V.; Mignon, L. Enhanced 5- HT2C receptor signaling is associated with haloperidol-induced early onset vacuous chewing in rats: implications for antipsychotic drug therapy. Psychopharmacology (Berl), 2005, 182(1), 84-94.
35. Kostrzewa, R.M.; Gong, L.; Brus, R. Serotonin (5-HT) systems mediate dopamine (DA) receptor supersensitivity. Acta Neurobiol. Exp. (Wars), 1993, 53(1), 31-41.
36. Mehta, A.; Eberle-Wang, K.; Chesselet, M.F. Increased m-CPPinduced oral dyskinesia after lesion of serotonergic neurons. Pharmacol. Biochem. Behav., 2001, 68(2), 347-353.
37. Dunlop, J.; Sabb, A.L.; Mazandarani, H.; Zhang, J.; Kalgaonker, S.; Shukhina, E.; Sukoff, S.; Vogel, R.L.; Stack, G.; Schechter, L.; Harrison, B.L.; Rosenzweig-Lipson, S. WAY-163909[(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indol e], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J.Pharmacol. Exp. Ther., 2005, 313(2), 862-869.
38. Beyeler, A.; Kadiri, N.; Navailles, S.; Boujema, M.B.; Gonon, F.; Moine, C.L.; Gross, C.; De Deurwaerdere, P. Stimulation of serotonin2C receptors elicits abnormal oral movements by acting on pathways other than the sensorimotor one in the rat basal ganglia. Neuroscience, 2010, 169(1), 158-170.
39. Marchese, G.; Bartholini, F.; Ruiu, S.; Casti, P.; Casu, G.L.; Pani, L. Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol. Eur. J.Pharmacol., 2004, 483(1), 65-69.
40. Naidu, P.S.; Kulkarni, S.K. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur. J. Pharmacol., 2001, 428(1), 81-86.
41. Shi, W.X.; Nathaniel, P.; Bunney, B.S. Ritanserin, a 5-HT2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons. J. Pharmacol. Exp. Ther., 1995, 274(2), 735-740.
42. Dekeyne, A.; Mannoury la Cour, C.; Gobert, A.; Brocco, M.; Lejeune, F.; Serres, F.; Sharp, T.; Daszuta, A.; Soumier, A.; Papp, M.; Rivet, J.M.; Flik, G.; Cremers, T.I.; Muller, O.; Lavielle, G.; Millan, M.J. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology (Berl), 2008, 199(4), 549-568.
43. Dekeyne, A.; Millan, M.J. Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization. Psychopharmacology (Berl), 2009, 203(2), 329-341.
44. Scarlota, L.C.; Harvey, J.A.; Aloyo, V.J. The role of serotonin-2 (5-HT2) and dopamine receptors in the behavioral actions of the 5- HT2A/2C agonist, DOI, and putative 5-HT2C inverse agonist, SR46349B. Psychopharmacology (Berl), 2011, 213(2-3), 393-401.
45. Murray, K.C.; Nakae, A.; Stephens, M.J.; Rank, M.; D'Amico, J.; Harvey, P.J.; Li, X.; Harris, R.L.; Ballou, E.W.; Anelli, R.; Heckman, C.J.; Mashimo, T.; Vavrek, R.; Sanelli, L.; Gorassini, M.A.; Bennett, D.J.; Fouad, K. Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. Nat. Med., 2010, 16(6), 694-700.
46. De Deurwaerdere, P.; Navailles, S.; Berg, K.A.; Clarke, W.P.; Spampinato, U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J. Neurosci., 2004, 24(13), 3235-3241.
47. Di Giovanni, G.; De Deurwaerdere, P.; Di Mascio, M.; Di Matteo, V.; Esposito, E.; Spampinato, U. Selective blockade of serotonin- 2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience, 1999, 91(2), 587-597.
48. Navailles, S.; De Deurwaerdère, P. The constitutive activity of 5- HT2C receptors as an additional modality of interaction of the serotonergic system in motor control. In: 5-HT2C Receptors in the Pathophysiology of CNS Disease, Di Giovanni, G., Di Matteo, V., Esposito, E., Eds.; Springer; 2010 pp. 187-214.
49. Chou-Green, J.M.; Holscher, T.D.; Dallman, M.F.; Akana, S.F. Compulsive behavior in the 5-HT2C receptor knockout mouse. Physiol. Behav., 2003, 78(4-5), 641-649.
50. Clemett, D.A.; Punhani, T.; Duxon, M.S.; Blackburn, T.P.; Fone, K.C. Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology, 2000, 39(1), 123-132.
51. Simansky, K.J.; Dave, K.D.; Inemer, B.R.; Nicklous, D.M.; Padron, J.M.; Aloyo, V.J.; Romano, A.G. A 5-HT2C agonist elicits hyperactivity and oral dyskinesia with hypophagia in rabbits. Physiol. Behav., 2004, 82(1), 97-107.
52. Eberle-Wang, K.; Mikeladze, Z.; Uryu, K.; Chesselet, M.F. Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats. J. Comp. Neurol., 1997, 384(2), 233-247.
53. Mengod, G.; Nguyen, H.; Le, H.; Waeber, C.; Lubbert, H.; Palacios, J.M. The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution. Neuroscience, 1990, 35(3), 577-591.
54. Pasqualetti, M.; Ori, M.; Castagna, M.; Marazziti, D.; Cassano, G.B.; Nardi, I. Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience, 1999, 92(2), 601-611.
55. De Deurwaerdère, P.; Mignon, L.; Chesselet, M. Physiological and pathophysiological aspects of 5-HT2C receptors in basal ganglia. In: 5-HT2C Receptors in the Pathophysiology of CNS Disease, Di Giovanni, G., Di Matteo, V., Esposito, E., Eds.; Springer Science: New York; 2010.
56. De Deurwaerdere, P.; Chesselet, M.F. Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats. J.Neurosci., 2000, 20(13), 5170-5178.
57. Plech, A.; Brus, R.; Kalbfleisch, J.H.; Kostrzewa, R.M. Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats. Psychopharmacology (Berl), 1995, 119(4), 466-473.
58. Adachi, K.; Hasegawa, M.; Fujita, S.; Sato, M.; Miwa, Y.; Ikeda, H.; Koshikawa, N.; Cools, A.R. Dopaminergic and cholinergic stimulation of the ventrolateral striatum elicit rat jaw movements that are funnelled via distinct efferents. Eur. J. Pharmacol., 2002, 442(1-2), 81-92.
59. De Deurwaerdère, P. L-DOPA and the 5-HT system in iatrogenic dyskinesia in parkinsonian rats: toward a double component involving 5-HT neurons and postsynaptic 5-HT2C receptors.: 3rd Mediterranean Conference of Neuroscience, Alexandria, Egypt: Front. Neurosci., 2009.
60. Liminga, U.; Johnson, A.E.; Andren, P.E.; Gunne, L.M. Modulation of oral movements by intranigral 5-hydroxytryptamine receptor agonists in the rat. Pharmacol.Biochem. Behav., 1993, 46(2), 427-433.
61. Di Giovanni, G.; Di Matteo, V.; La Grutta, V.; Esposito, E. m- Chlorophenylpiperazine excites non-dopaminergic neurons in the rat substantia nigra and ventral tegmental area by activating serotonin-2C receptors. Neuroscience, 2001, 103(1), 111-116.
62. Invernizzi, R.W.; Pierucci, M.; Calcagno, E.; Di Giovanni, G.; Di Matteo, V.; Benigno, A.; Esposito, E. Selective activation of 5- HT(2C) receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study. Neuroscience, 2007, 144(4), 1523-1535.
63. Rick, C.E.; Stanford, I.M.; Lacey, M.G. Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: evidence for a direct action mediated by 5-hydroxytryptamine2C receptors. Neuroscience, 1995, 69(3), 903-913.
64. Stanford, I.M.; Kantaria, M.A.; Chahal, H.S.; Loucif, K.C.; Wilson, C.L. 5-Hydroxytryptamine induced excitation and inhibition in the subthalamic nucleus: action at 5-HT(2C), 5-HT(4) and 5-HT(1A) receptors. Neuropharmacology, 2005, 49(8), 1228-1234.
65. Xiang, Z.; Wang, L.; Kitai, S.T. Modulation of spontaneous firing in rat subthalamic neurons by 5-HT receptor subtypes. J. Neurophysiol., 2005, 93(3), 1145-1157.
66. Chen, L.; Yung, K.K.; Chan, Y.S.; Yung, W.H. 5-HT excites globus pallidus neurons by multiple receptor mechanisms. Neuroscience, 2008, 151(2), 439-451.
67. Kita, H.; Chiken, S.; Tachibana, Y.; Nambu, A. Serotonin modulates pallidal neuronal activity in the awake monkey. J. Neurosci., 2007, 27(1), 75-83.
68. Leslie, R.A.; Moorman, J.M.; Coulson, A.; Grahame-Smith, D.G. Serotonin2/1C receptor activation causes a localized expression of the immediate-early gene c-fos in rat brain: evidence for involvement of dorsal raphe nucleus projection fibres. Neuroscience, 1993, 53(2), 457-463.
69. Singewald, N.; Salchner, P.; Sharp, T. Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol. Psychiatry, 2003, 53(4), 275-283.
70. Adachi, K.; Hasegawa, M.; Fujita, S.; Lee, J.; Cools, A.R.; Waddington, J.L.; Koshikawa, N. Prefrontal, accumbal [shell] and ventral striatal mechanisms in jaw movements and non-cyclasecoupled dopamine D1-like receptors. Eur. J. Pharmacol., 2003, 473(1), 47-54.
71. Kadiri, N.; Lagiere, M.; Le Moine, C.; Millan, M.J.; De Deurwaerdere, P.; Navailles, S. Diverse effects of 5-HT(2C) receptor blocking agents on c-Fos expression in the rat basal ganglia. Eur. J. Pharmacol., 2012, 689(1-3), 8-16.
72. Zhang, Q.J.; Liu, X.; Liu, J.; Wang, S.; Ali, U.; Wu, Z.H.; Wang, T. Subthalamic neurons show increased firing to 5-HT2C receptor activation in 6-hydroxydopamine-lesioned rats. Brain Res., 2009, 1256, 180-189.
73. Stark, J.A.; Davies, K.E.; Williams, S.R.; Luckman, S.M. Functional magnetic resonance imaging and c-Fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine. Neuroimage, 2006, 31(3), 1228-1237.
74. Stark, J.A.; McKie, S.; Davies, K.E.; Williams, S.R.; Luckman, S.M. 5-HT(2C) antagonism blocks blood oxygen level-dependent pharmacological-challenge magnetic resonance imaging signal in rat brain areas related to feeding. Eur. J. Neurosci., 2008, 27(2), 457-465.
75. Carlson, B.B.; Wisniecki, A.; Salamone, J.D. Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of Parkinsonian tremor. Psychopharmacology (Berl), 2003, 165(3), 229-237.
76. Rosengarten, H.; Schweitzer, J.W.; Friedhoff, A.J. The effect of novel antipsychotics in rat oral dyskinesia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1999, 23(8), 1389-1404.
77. Brus, R.; Plech, A.; Kostrzewa, R.M. Enhanced quinpirole response in rats lesioned neonatally with 5,7-dihydroxytryptamine. Pharmacol. Biochem. Behav., 1995, 50(4), 649-653.
78. Deniau, J.M.; Menetrey, A.; Charpier, S. The lamellar organization of the rat substantia nigra pars reticulata: segregated patterns of striatal afferents and relationship to the topography of corticostriatal projections. Neuroscience, 1996, 73(3), 761-781.
79. Creed, M.; Hamani, C.; Nobrega, J.N. Deep brain stimulation of the subthalamic or entopeduncular nucleus attenuates vacuous chewing movements in a rodent model of tardive dyskinesia. Eur. Neuropsychopharmacol., 2011, 21(5), 393-400.
80. Caretti, V.; Stoffers, D.; Winogrodzka, A.; Isaias, I.U.; Costantino, G.; Pezzoli, G.; Ferrarese, C.; Antonini, A.; Wolters, E.C.; Booij, J. Loss of thalamic serotonin transporters in early drug-naive Parkinson's disease patients is associated with tremor: an [(123)I] beta-CIT SPECT study. J. Neural. Transm., 2008, 115(5), 721-729.
81. Politis, M.; Wu, K.; Loane, C.; Quinn, N.P.; Brooks, D.J.; Oertel, W.H.; Bjorklund, A.; Lindvall, O.; Piccini, P. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci. Transl. Med., 2012, 4(128), 128-141.
82. Casey, D.E. Neuroleptic-induced parkinsonism increases with repeated treatment in monkeys. Psychopharmacol. Ser., 1987, 3, 243-247.
83. Jeste, D.V.; Caligiuri, M.P. Tardive dyskinesia. Schizophr. Bull., 1993, 19(2), 303-315.
84. Waddington, J.L. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology (Berl), 1990, 101(4), 431-447.
85. Waddington, J.L.; Cross, A.J.; Gamble, S.J.; Bourne, R.C. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science, 1983, 220(4596), 530-532.
86. Wadenberg, M.L.; Soliman, A.; VanderSpek, S.C.; Kapur, S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology, 2001, 25(5), 633-641.
87. Reynolds, G.P.; Templeman, L.A.; Zhang, Z.J. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2005, 29(6), 1021-1028.
88. Richtand, N.M.; Welge, J.A.; Logue, A.D.; Keck, P.E., Jr.; Strakowski, S.M.; McNamara, R.K. Role of serotonin and dopamine receptor binding in antipsychotic efficacy. Prog. Brain Res., 2008, 172, 155-175.
89. Ikram, H.; Samad, N.; Haleem, D.J. Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia. Pak. J. Pharm. Sci., 2007, 20(3), 188-195.
90. Creed-Carson, M.; Oraha, A.; Nobrega, J.N. Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats. Behav. Brain Res., 2011, 219(2), 273-279.
91. Haleem, D.J.; Samad, N.; Haleem, M.A. Reversal of haloperidolinduced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. Pharmacol. Biochem. Behav., 2007, 87(1), 115-121.
92. Haleem, D.J.; Samad, N.; Haleem, M.A. Reversal of haloperidolinduced extrapyramidal symptoms by buspirone: a time-related study. Behav. Pharmacol., 2007, 18(2), 147-153.
93. Samad, N.; Khan, A.; Perveen, T.; Haider, S.; Abdul Haleem, M.; Haleem, D.J. Increase in the effectiveness of somatodendritic 5- HT-1A receptors in a rat model of tardive dyskinesia. Acta Neurobiol. Exp. (Wars), 2007, 67(4), 389-397.
94. Stoessl, A.J.; Rajakumar, N. Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat. Synapse, 1996, 24(3), 256-261.
95. Navailles, S.; De Deurwaerdere, P. Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease. Mol. Neurobiol., 2012, 45(1), 173-185.
96. Bruggeman, R.; Heeringa, M.; Westerink, B.H.; Timmerman, W. Combined 5-HT2/D2 receptor blockade inhibits the firing rate of SNR neurons in the rat brain. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2000, 24(4), 579-593.
97. Hornykiewicz, O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol.Rev., 1966, 18(2), 925-964.
98. Albin, R.L.; Young, A.B.; Penney, J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci., 1989, 12(10), 366-375.
99. Obeso, J.A.; Rodriguez-Oroz, M.C.; Rodriguez, M.; Lanciego, J.L.; Artieda, J.; Gonzalo, N.; Olanow, C.W. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci, 2000, 23(10 Suppl), S8-19.
100. Kostrzewa, R.M. Dopamine receptor supersensitivity. Neurosci. Biobehav.Rev., 1995, 19(1), 1-17.
101. Mrini, A.; Soucy, J.P.; Lafaille, F.; Lemoine, P.; Descarries, L. Quantification of the serotonin hyperinnervation in adult rat neostriatum after neonatal 6-hydroxydopamine lesion of nigral dopamine neurons. Brain Res., 1995, 669(2), 303-308.
102. Navailles, S.; De Deurwaerdere, P. Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPAInduced Dyskinesia. Parkinsons Dis., 2012, 2012, 323686.
103. Kish, S.J.; Tong, J.; Hornykiewicz, O.; Rajput, A.; Chang, L.J.; Guttman, M.; Furukawa, Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain, 2008, 131(Pt 1), 120-131.
104. Scholtissen, B.; Verhey, F.R.; Adam, J.J.; Weber, W.; Leentjens, A.F. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance. Clin. Neuropharmacol., 2006, 29(5), 276-285.
105. Braak, H.; Rub, U.; Gai, W.P.; Del Tredici, K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm., 2003, 110(5), 517-536.
106. Delaville, C.; Navailles, S.; Benazzouz, A. Effects of noradrenaline and serotonin depletions on the neuronal activity of globus pallidus and substantia nigra pars reticulata in experimental parkinsonism. Neuroscience, 2012, 202, 424-433.
107. Gong, L.; Kostrzewa, R.M.; Li, C. Neonatal 6-hydroxydopamine and adult SKF 38393 treatments alter dopamine D1 receptor mRNA levels: absence of other neurochemical associations with the enhanced behavioral responses of lesioned rats. J. Neurochem., 1994, 63(4), 1282-1290.
108. Numan, S.; Lundgren, K.H.; Wright, D.E.; Herman, J.P.; Seroogy, K.B. Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res. Mol. Brain Res., 1995, 29(2), 391-396.
109. Waeber, C.; Palacios, J.M. Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study. Neuroscience, 1989, 32(2), 337-347.
110. Fox, S.H.; Brotchie, J.M. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov. Disord., 2000, 15(6), 1064-1069.
111. Gong, L.; Kostrzewa, R.M.; Perry, K.W.; Fuller, R.W. Doserelated effects of a neonatal 6-OHDA lesion on SKF 38393- and mchlorophenylpiperazine- induced oral activity responses of rats. Brain Res. Dev. Brain Res., 1993, 76(2), 233-238.
112. Belforte, J.E.; Pazo, J.H. Turning behavior induced by stimulation of the 5-HT receptors in the subthalamic nucleus. Eur. J. Neurosci., 2004, 19(2), 346-355.
113. Navailles, S.; De Deurwaerdere, P. Presynaptic control of serotonin on striatal dopamine function. Psychopharmacology (Berl), 2011, 213(2-3), 213-242.
114. Fox, S.H.; Moser, B.; Brotchie, J.M. Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6- hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol., 1998, 151(1), 35-49.
115. Fox, S.; Brotchie, J. Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat. Eur. J. Pharmacol., 1996, 301(1-3), 27-30.
116. Fox, S.H.; Brotchie, J.M. 5-HT(2C) receptor antagonists enhance the behavioral response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. Eur. J. Pharmacol., 2000, 398(1), 59-64.
117. Knight, A.R.; Misra, A.; Quirk, K.; Benwell, K.; Revell, D.; Kennett, G.; Bickerdike, M. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5- HT(2C) receptors. Naunyn Schmiedebergs Arch. Pharmacol., 2004, 370(2), 114-123.
118. Wood, M.D.; Reavill, C.; Trail, B.; Wilson, A.; Stean, T.; Kennett, G.A.; Lightowler, S.; Blackburn, T.P.; Thomas, D.; Gager, T.L.; Riley, G.; Holland, V.; Bromidge, S.M.; Forbes, I.T.; Middlemiss, D.N. SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology, 2001, 41(2), 186-199.